Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Genital Herpes Simplex Type 2: early-phase trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Genital Herpes Simplex Type 2: 4 US clinical trials tracked, none currently recruiting.
Genital Herpes Simplex Type 2 is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Genocea Biosciences, running 3 of these trials.
Enrollment posture brief
Registry condition genital-herpes-simplex-type-2
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Genital Herpes Simplex Type 2 has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Genital Herpes Simplex Type 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Genital Herpes Simplex Type 2 is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
BioNTech SE
NCT05432583
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
Genocea Biosciences
NCT02114060
Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity
Genocea Biosciences
NCT02910284
Evaluating New Formulation of Therapeutic HSV-2 Vaccine
Genocea Biosciences
NCT02515175
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Genital Herpes Simplex Type 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Genital Herpes Simplex Type 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Genital Herpes Simplex Type 2 page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Genital Herpes Simplex Type 2 trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Genocea Biosciences sponsors the most Genital Herpes Simplex Type 2 trials on record, review their full trial history before evaluating a specific study. See Genocea Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Genital Herpes Simplex Type 2 condition card totals 4 registered trials; most-linked intervention Matrix-M2 Adjuvant (75μg); top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.